User login
Key clinical point: Treatment with the second-generation (2G) tyrosine kinase inhibitors (TKI) before allogeneic hematopoietic cell transplantation (allo-HCT) is feasible without any detrimental posttransplant outcomes or additional transplant-related toxicities in patients with chronic myeloid leukemia (CML).
Major finding: During a median follow-up of 37 months posttransplantation, 92% of patients had successful grafts, whereas 3% and 5% of patients experienced primary and secondary graft failure, respectively. At 5 years, nonrelapse mortality, chronic graft versus host disease, and overall survival were 24% (95% CI 19%-29%), 60% (95% CI 54%-66%), and 56% (95% CI 50%-62%), respectively.
Study details: This prospective study included 383 adult patients with CML previously treated with dasatinib (40%), nilotinib (17%), or sequential dasatinib and nilotinib with or without bosutinib or ponatinib (43%) who first underwent allo-HCT.
Disclosures: This study was supported by Novartis. Some investigators reported travel grants, honoraria, speaker fees, advisory board membership, or clinical trial independent data monitoring committee membership with various pharmaceutical companies, including Novartis.
Source: Masouridi-Levrat S et al. Bone Marrow Transplant. 2021 Oct 1. doi: 10.1038/s41409-021-01472-x.
Key clinical point: Treatment with the second-generation (2G) tyrosine kinase inhibitors (TKI) before allogeneic hematopoietic cell transplantation (allo-HCT) is feasible without any detrimental posttransplant outcomes or additional transplant-related toxicities in patients with chronic myeloid leukemia (CML).
Major finding: During a median follow-up of 37 months posttransplantation, 92% of patients had successful grafts, whereas 3% and 5% of patients experienced primary and secondary graft failure, respectively. At 5 years, nonrelapse mortality, chronic graft versus host disease, and overall survival were 24% (95% CI 19%-29%), 60% (95% CI 54%-66%), and 56% (95% CI 50%-62%), respectively.
Study details: This prospective study included 383 adult patients with CML previously treated with dasatinib (40%), nilotinib (17%), or sequential dasatinib and nilotinib with or without bosutinib or ponatinib (43%) who first underwent allo-HCT.
Disclosures: This study was supported by Novartis. Some investigators reported travel grants, honoraria, speaker fees, advisory board membership, or clinical trial independent data monitoring committee membership with various pharmaceutical companies, including Novartis.
Source: Masouridi-Levrat S et al. Bone Marrow Transplant. 2021 Oct 1. doi: 10.1038/s41409-021-01472-x.
Key clinical point: Treatment with the second-generation (2G) tyrosine kinase inhibitors (TKI) before allogeneic hematopoietic cell transplantation (allo-HCT) is feasible without any detrimental posttransplant outcomes or additional transplant-related toxicities in patients with chronic myeloid leukemia (CML).
Major finding: During a median follow-up of 37 months posttransplantation, 92% of patients had successful grafts, whereas 3% and 5% of patients experienced primary and secondary graft failure, respectively. At 5 years, nonrelapse mortality, chronic graft versus host disease, and overall survival were 24% (95% CI 19%-29%), 60% (95% CI 54%-66%), and 56% (95% CI 50%-62%), respectively.
Study details: This prospective study included 383 adult patients with CML previously treated with dasatinib (40%), nilotinib (17%), or sequential dasatinib and nilotinib with or without bosutinib or ponatinib (43%) who first underwent allo-HCT.
Disclosures: This study was supported by Novartis. Some investigators reported travel grants, honoraria, speaker fees, advisory board membership, or clinical trial independent data monitoring committee membership with various pharmaceutical companies, including Novartis.
Source: Masouridi-Levrat S et al. Bone Marrow Transplant. 2021 Oct 1. doi: 10.1038/s41409-021-01472-x.